Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$7.56K$7.56Kderived+57.2% vs Q4 2021 Net Income-$899.05K-$899.05KderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$1,142,004N/M Operating Cash Flowderived-$315,505N/M Free Cash Flowderived-$315,505N/M Margins · derivedOperating margin-15103.9%+143921.0 pt vs Q4 2021
Net margin-11890.6%+155486.6 pt vs Q4 2021
ended Dec 31, 2022 · filed Apr 17, 2023 · 107 d after period end